Effects of α-linolenic Acid Supplementation on Hemostasis in Nondiabetic and Hypercholesterolemic Subjects
Status and phase
Conditions
Treatments
Details and patient eligibility
About
This study evaluates whether ALA intake alters total cholesterol and homeostatic factors and the relationship between these alteration and lipoprotein associated phospholipase A2 (Lp-PLA2) activity.
Full description
An 8-week, randomized, double-blind, placebo-controlled study was conducted with 86 nondiabetic and borderline-to-moderate hypercholesterolemic (200mg/dL ≤ serum cholesterol ≤ 300mg/dL) subjects, not taking any medications and supplements to affect lipid metabolism, platelet function and inflammation, divided into two groups: an α-linolenic acid (ALA) group [1.2 g (two capsules) of perilla oil daily; 497 mg ALA] and a placebo group (1.2 g of medium-chain triglyceride oil daily).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Voluntarily agree to participate and sign in informed consent form
- Adults aged 40-70
- Nondiabetic and hypercholesterolemic subjects (serum cholesterol ≥ 200 mg/dL)
Exclusion criteria
- Subjects taking any medication or supplements known to affect lipid metabolism or platelet function, n-3 fatty acid supplementation or n-3 fatty acid-rich fish more than two times per week
- Following diseases: dyslipidemia, hypertension, diabetes, liver disease, renal disease, pancreatitis, cardiovascular disease, gastrointestinal disease, cancer, or any other disease requiring treatment
- Participation in clinical trials of any drug or supplement within 30 days prior to the participation of the study
- Pregnant or lactating women, alcoholic, mental patient
- Judged to be inappropriate for the study by the investigator after reviewing other reasons
Trial design
Primary purpose
Allocation
Interventional model
Masking
86 participants in 2 patient groups, including a placebo group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal